Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Medical
EPIC: NNVC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
NanoViricides
www.nanoviricides.com

NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.

Full NanoViricides profile here
Pdf

NanoViricides granted key U.S. patent

7th May 2012, 12:57 pm by Brad Lemaire
NanoViricides granted key U.S. patent

NanoViricides (OTCBB:NNVC) said the U.S. Patents and Trademarks office on Monday has granted the company a patent, on which the company’s technology is based.

The U.S. Patent No. 8,173,764 relates to "Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers" and will be issued on May 8.

The company said that the issuance notification was received from the U.S. Patents and Trademarks office last week.

The patent term is expected to last until October 1, 2026, with the possibility of further extensions in compensation for time spent in clinical trials.

Additionally, the patent covers a broad range of biomimetic technologies.

NanoViricides will hold exclusive and perpetual worldwide licenses to these claims for a broad range of antiviral applications and diseases.

"These biomimetic features allow us to make the nanoviricide look like a host-cell membrane to the virus, with the goal of deceiving the virus to land on it and thereupon destroy itself," said Anil Diwan president of NanoViricides.

"This patent establishes a fundamentally new direction in developing biomimetic approaches," Diwan added.

Meanwhile, patents have also been issued in New Zealand and South Africa, and as a regional patent valid in 16 other African states. Further issuances are slated in Europe, and in many other countries around the world.

The patents are being issued to the founders of the company, and have been assigned to AllExcel Inc. which has transferred the intellectual property to TheraCour Pharma.

In a statement, chief executive Eugene Seymour said: "Based on the tremendous effectiveness that our NanoViricides drugs have shown against a large number of viral diseases in several very stringent animal models this technology spells a fundamental change in how medicines will be developed in the future."

The development stage company designs drugs to specifically attack virus particles and to dismantle them.

NanoViricides drug pipeline includes candidates to treat diseases like H5N1 bird flu, HIV, hepatitis C, rabies, dengue fever and the Ebola virus.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here